Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
3(100.0%)
3Total
Phase 4(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02180100Phase 4Completed

Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

Role: collaborator

NCT02357615Phase 4Unknown

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure

Role: lead

NCT02031861Phase 4Completed

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

Role: lead

All 3 trials loaded